Exeliom Biosciences is a clinical-stage biotechnology company focused on developing innovative therapies that leverage the innate immune regulatory mechanisms associated with the microbiome. Their lead drug candidate, EXL01, is a first-in-class oral treatment designed to enhance the immune response in patients suffering from conditions where dysregulated immunity limits the effectiveness of existing therapies. Specifically, EXL01 utilizes the immunomodulatory properties of the commensal bacterium Faecalibacterium prausnitzii to facilitate the resolution of inflammation in a non-suppressive manner. This approach aims to improve patient outcomes in various indications, including inflammatory bowel diseases like Crohn's disease, solid tumor cancers, and recurrent Clostridium difficile infections.

The therapeutic potential of EXL01 is being evaluated through multiple clinical trials, including a Phase I study for Crohn's disease and Phase II trials in combination with immune checkpoint inhibitors for cancer treatment. The drug's mechanism of action involves promoting a regulatory phenotype in antigen-presenting cells, which helps to downregulate pro-inflammatory T cells while enhancing specific regulatory T cell populations. This dual action not only aims to reduce inflammation but also to synergize with existing cancer therapies, thereby offering a promising avenue for patients who have limited treatment options. Overall, Exeliom Biosciences is committed to exploring novel therapeutic solutions that harness the power of the microbiome to improve patient care.

France

At Exeliom Biosciences, we develop single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with specific focus on inflammatory bowel diseases (IBD), and Crohn’s Disease as a first indication

Exeliom Biosciences

Company Details